Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Evaluating the impact of BRAF reflex mutation testing on the management of melanoma, colorectal and lung cancers

FY 2022-23

Summary
Melanoma is a type of skin cancer diagnosed in over 8,000 Canadians each year, while approximately 1,300 Canadians die from this cancer. Understanding how chemical reactions and specific groups of molecules can control the function of cells has allowed for the development of treatments that target specific molecules that have been mutated in certain cancers. An important mutation found in melanoma, lung cancers, and colorectal cancers is one that occurs in what is known as the BRAF oncogene. BRAF-targeted treatments have since emerged as an important option for these types of cancers. However, there is currently variability in the guidelines pertaining to testing for this mutation. Reflex tests refer to additional testing performed when an initial result is positive or outside normal parameters, such as molecular testing following a the diagnosis of a specific cancer. For a variety of cancers, reflex molecular testing was demonstrated to reduce the time to treatment initiation and, thus, may potentially impact survival outcomes. Whether or not BRAF mutation reflex testing will lead to a reduction in time to treatment initiation and its impact on survival for melanoma, colorectal or lung cancers has not yet been evaluated. This study aims to determine the impact of testing for BRAF-mutation status in colorectal, lung cancers and melanoma on outcomes such as treatment selection and initiation of targeted treatments, response to therapy and cancer-related outcomes such as complications, survival and death. This project will help to optimize the approach to molecular testing, accessibility to targeted therapies, and cancer outcomes as they relate BRAF-mutation reflex testing in melanoma, lung cancers, and colorectal cancers.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486343
Name
Gresham Louise M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the impact of BRAF reflex mutation testing on the management of melanoma, colorectal and lung cancers
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Braf Mutation; Cancer; Colorectal Cancer; Immunotherapy; Lung Cancer; Management; Melanoma; Oncology Outcomes; Reflex Testing
Abstract
Melanoma is a type of skin cancer diagnosed in over 8,000 Canadians each year, while approximately 1,300 Canadians die from this cancer. Understanding how chemical reactions and specific groups of molecules can control the function of cells has allowed for the development of treatments that target specific molecules that have been mutated in certain cancers. An important mutation found in melanoma, lung cancers, and colorectal cancers is one that occurs in what is known as the BRAF oncogene. BRAF-targeted treatments have since emerged as an important option for these types of cancers. However, there is currently variability in the guidelines pertaining to testing for this mutation. Reflex tests refer to additional testing performed when an initial result is positive or outside normal parameters, such as molecular testing following a the diagnosis of a specific cancer. For a variety of cancers, reflex molecular testing was demonstrated to reduce the time to treatment initiation and, thus, may potentially impact survival outcomes. Whether or not BRAF mutation reflex testing will lead to a reduction in time to treatment initiation and its impact on survival for melanoma, colorectal or lung cancers has not yet been evaluated. This study aims to determine the impact of testing for BRAF-mutation status in colorectal, lung cancers and melanoma on outcomes such as treatment selection and initiation of targeted treatments, response to therapy and cancer-related outcomes such as complications, survival and death. This project will help to optimize the approach to molecular testing, accessibility to targeted therapies, and cancer outcomes as they relate BRAF-mutation reflex testing in melanoma, lung cancers, and colorectal cancers.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gresham, Louise M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~